BRAF and colorectal carcinoma: Blockade of oncogenic receptor tyrosine kinases in advanced CRC patients is hampered by intrinsic and acquired resistance, even when vertical combinations of inhibitors (for instance EGFR, BRAF and MEK triplet combinatorial regimens) are applied31.